News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Genetic markers being used to target oral hepatitis C drug

Please note embargo:


Genetic markers being used to target new oral hepatitis C drug

A person’s genetic makeup will be used to target a new funded oral treatment for hepatitis C patients from 1 September.

PHARMAC will begin funding boceprevir (Victrelis) from 1 September 2013 for certain patients with the chronic liver infection. Boceprevir will be funded when used as a triple therapy in combination with pegylated interferon with ribavirin.

PHARMAC Medical Director Dr Peter Moodie says many hepatitis C patients do not respond well to current treatments, but that this could improve with the addition of boceprevir.

“Clinical evidence shows that, given the genetic characteristics of a patient, a simple genetic test can fairly accurately predict how they might respond to treatment,” says Dr Moodie.

“There is a group who we know respond poorly to current treatment. They are the ones we think will benefit most from the addition of this new treatment.”

About 25-35% of patients with certain genes showed a sustained response to the currently available treatment of pegylated interferon and ribavirin. By adding boceprevir to the treatment of these patients, the response rate increases to 70–75%.

As well as adding greater effectiveness to available treatments, Dr Moodie says boceprevir is the first funded oral treatment specifically for hepatitis C.

Patients will be genetically tested to determine whether they qualify for boceprevir (in combination with pegylated interferon and ribavirin) as a first-line treatment.

Boceprevir will also be funded for people who have tried but not responded completely to a course of pegylated interferon and ribavirin.

Dr Moodie says though many people live with hepatitis C without ever knowing it, the infection can cause significant health issues including hepatocellular carcinoma, liver failure, which may require a liver transplant.

Pharmacological treatment aims to reduce the likelihood of these transplants being required. In total, PHARMAC expects around 300 patients to start triple therapy in the next year.

In addition to funding boceprevir, PHARMAC has negotiated a price reduction for the Pegasys brand of pegylated interferon with ribavirin. Together, the funding of these hepatitis C treatments will cost $17.8 million over five years, with some of this cost being refunded through confidential rebates negotiated with both suppliers.


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis: Review - A Girl Named Mo

Moana Ete brought her three-piece band A Girl Named Mo to Wellington's intimate and iconic Bats Theatre last week for a five-night residency. Each show was recorded and filmed live for the release of her debut album 'Platonic/Romantic' on Loop records later this year. More>>

For The Birds: Who Will Be Crowned Bird Of The Year?

The competition involves well-known and enthusiastic New Zealanders acting as ‘campaign managers’ for their favourite birds with many going to great lengths to get New Zealanders to vote for their chosen bird... More>>


  • Greening the Red Zone - Bird of the year heats up: kōtare concedes, backs kea
  • Image Out-Link - Giselle Clarkson on Twitter
  • Gordon Campbell: On Bob Dylan's Nobel (And The Surplus)

    So Bob Dylan has just won the Nobel Prize for… Literature? Wow. I’d be just as happy if he’d won for his work on particle physics (“One Grain of Sand”, “Simple Twist of Fate”) or got the Economics prize for his work on the theory of contracting (“Don’t Think Twice Its Alright”) ... More>>


    Scoop Review Of Books: Whose Goat Was That?

    Mysterious Mysteries of Aro Valley is a sharp, satirical and sometimes downright scary romp through and around that valley in ways that made me question the realities of the places I thought I knew so well. More>>


    NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

    Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


    Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

    Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


    Get More From Scoop



    Search Scoop  
    Powered by Vodafone
    NZ independent news